Global Estrogen Receptor Agonist Market By Products (Endogenous Estrogen Receptor Agonist, Selective Estrogen Receptor Agonist, Others); By Clinical Indication (Breast Cancer, Fertility, PCOS, Osteoporosis, Neurodegenerative Disorders (Including Multiple sclerosis (MS)), Inflammatory Diseases, Cardiovascular Health, Other); By Route of Administration (Oral, Parenteral); By Distribution Channel (Online, Offline); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia(Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia) Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global estrogen receptor agonist market is projected to be driven by the increasing prevalence of cardiovascular disease across the globe. Cardiovascular disease is the leading cause of death and more than 17 million people die worldwide from CVD per year. This rising prevalence has increased the demand for various therapies to treat CVD. As per the study published in NCBI, epidemiological studies indicate that premenopausal women are more protected against the development of CVD compared to age-matched men as estrogen modulates cardiovascular physiology and function and could potentially serve as a cardioprotective agent. According to the American Heart Association, hypertension is the most significant risk factor for CVD and half of CVD events are attributed to hypertension. E2 is the most common form of circulating estrogen in the body and is known to possess powerful acute and chronic vasodilator activity, thereby aiding to lower blood pressure and guard against hypertension.
The rising number of patients suffering from breast cancer is anticipated to drive the estrogen receptor agonist market. As per the WHO, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally in 2020. Moreover, the increasing incidences of women suffering from osteoporosis post menopause has raised the demand for estrogen receptor agonists. In order to cater the increasing demand, many drugs have been approved to provide the line of treatment. For instance, Raloxifene (Evista) which belongs to a class of drugs called selective estrogen receptor modulators (SERMs) is an FDA-approved drug for the prevention and treatment of osteoporosis in postmenopausal women. Also, it helps to reduce the risk of invasive breast cancer in postmenopausal women at high risk or with osteoporosis. Moreover, the increasing R&D activities and key players adopting various strategies such as product development, collaborations, etc. is impelling the market growth. for instance, in February 2022, Veru Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly to focus on developing novel medicines for the management of breast and prostate cancer.
The outbreak of COVID-19 pandemic had a significant impact on global estrogen receptor agonist market due to disruption in research activities as the entire focus was on the drug development of COVID-19. Also, the disruption in supply chain operations affected the drug market in a negative way.
In terms of revenue, the global estrogen receptor agonist market is anticipated to grow at a CAGR of 15.76% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Estrogen Receptor Agonist Market Revenue & Forecast, (US$ Million), 2015 – 2030
Product Outlook
Based on product, the global estrogen receptor agonist market has been segmented into endogenous estrogen receptor agonist, selective estrogen receptor agonist, and others. The selective estrogen receptor agonist segment accounted for the largest market in 2021 as they are widely used to treat osteoporosis, breast cancer, postmenopausal symptoms, and these drugs have can act as an estrogen agonist depending on the target tissue. Also, several selective estrogen receptor agonist are being developed such as triphenylethylenes (tamoxifen and its derivatives: toremifene, droloxifene and idoxifene), chromans (levormeloxifene), benzothiophenes (raloxifene) which is driving the segment growth. Moreover, these drugs have high affinity towards estrogen receptors, thereby enhancing patient outcomes.
Clinical Indication Outlook
Based on clinical indication type, the global estrogen receptor agonist market is bifurcated into breast cancer, fertility, PCOS, osteoporosis, neurodegenerative disorders (Including Multiple sclerosis (MS). Among these, the breast cancer segment dominated the market in 2021 owing to increasing research and development on the product development to treat breast cancer. For instance, toremifene, tamoxifen, etc are FDA approved drugs to treat breast cancer.
Route of Administration Outlook
Based on route of administration, the global estrogen receptor agonist market is bifurcated into oral and parenteral. The oral route of administration segment holds the largest market in 2021. This growth is attributed to the advantages it offers such as non-invasiveness, patient compliance and convenience of drug administration. Also, the compliance of patients to oral formulations is generally higher than that to other parenteral, thereby driving the market.
Distribution Channel Outlook
Based on distribution channel, the global estrogen receptor agonist market is bifurcated into offline and online. The offline segment dominated the market in 2021 owing to the presence of long chain of pharmacies. Also, the increasing demand of prescription drugs is impelling the market growth. Moreover, expansion of retail pharmacies across the globe is driving the segment’s growth.
Region Outlook
Based on the regions, North America holds the prominent position owing to increasing prevalence of chronic diseases in the region such as cancer, diabetes, CVDs, etc. Also, the increasing investment by public and private sector in the research and development activities is adding fuel to the estrogen receptor agonist market. Moreover, the presence of well-developed healthcare infrastructure is another factor contributing for North America to hold the lion’s share of the revenue in 2021.
Competitive Landscape
The report provides both, qualitative and quantitative research of global estrogen receptor agonist market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key players operating in the global estrogen receptor agonist market are:
- AstraZeneca
- Eli Lilly and Company
- ESTRIGENIX
- Karo Pharma AB
- Merck KGaA
- Oasmia Pharmaceutical AB
- Oncternal Therapeutics.
- Pfizer Inc.
- Tocris Bioscience
- Tokyo Chemical Industry Co., Ltd
- Other Market Participants
Global Estrogen Receptor Agonist Market
By Product Type
- Endogenous Estrogen Receptor Agonist
- Selective Estrogen Receptor Agonist
- Others
By Clinical Indication
- Breast Cancer
- Fertility
- PCOS
- Osteoporosis
- Neurodegenerative Disorders (Including Multiple sclerosis (MS))
- Inflammatory Diseases
- Cardiovascular Health
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Online
- Offline
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market Scope
1.1.
Market Segmentation
1.2.
Years Considered
1.2.1.
Historic Years: 2015 - 2020
1.2.2.
Base Year: 2021
1.2.3.
Forecast Years: 2022 – 2030
2.
Key Target Audiences
3. Research Methodology
3.1.
Primary Research
3.1.1. Research Questionnaire
3.1.2.
Global Percentage Breakdown
3.1.3.
Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary
Research
3.2.1. Paid Databases
3.2.2.
Secondary Sources
3.3. Market Size Estimates
3.3.1.
Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5. Holistic Overview of Estrogen Receptor
Agonist Market
6.
Market Synopsis: Estrogen
Receptor Agonist Market
7. Estrogen Receptor
Agonist Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1. Product Definition
7.1.2.
Industry Development
7.2. Market Dynamics
7.2.1.
Drivers
7.2.2. Restraints
7.2.3.
Opportunities
7.3.
Trends in Estrogen Receptor
Agonist Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Estrogen Receptor Agonist
Market
7.6. Porter’s Five Force Analysis
7.7.
Impact of Covid-19 on Estrogen Receptor Agonist Market
8.
Global Estrogen Receptor Agonist Market Analysis and Forecasts, 2022 – 2030
8.1.
Overview
8.1.1. Global Estrogen
Receptor Agonist Market
Revenue (US$ Mn)
8.2. Global
Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Product Type
8.2.1. Endogenous Estrogen Receptor
Agonist
8.2.1.1.
Definition
8.2.1.2.
Market Estimation and Penetration,
2015 – 2021
8.2.1.3.
Market Forecast, 2022 – 2030
8.2.1.4.
Compound Annual Growth Rate (CAGR)
8.2.1.5.
Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1.
Market Estimation, 2015 – 2021
8.2.1.5.1.2.
Market Forecast, 2022 – 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1.
Market Estimation, 2015 – 2021
8.2.1.5.2.2.
Market Forecast, 2022 – 2030
8.2.1.5.3.
Asia Pacific
8.2.1.5.3.1.
Market Estimation, 2015 – 2021
8.2.1.5.3.2.
Market Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1.
Market Estimation, 2015 – 2021
8.2.1.5.4.2.
Market Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1.
Market Estimation, 2015 – 2021
8.2.1.5.5.2.
Market Forecast, 2022 – 2030
8.2.2.
Selective Estrogen Receptor
Agonist
8.2.2.1.
Definition
8.2.2.2.
Market Estimation and Penetration,
2015 – 2021
8.2.2.3.
Market Forecast, 2022 – 2030
8.2.2.4.
Compound Annual Growth Rate (CAGR)
8.2.2.5.
Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1.
Market Estimation, 2015 – 2021
8.2.2.5.1.2.
Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1.
Market Estimation, 2015 – 2021
8.2.2.5.2.2.
Market Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1.
Market Estimation, 2015 – 2021
8.2.2.5.3.2.
Market Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1.
Market Estimation, 2015 – 2021
8.2.2.5.4.2.
Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin America
8.2.2.5.5.1.
Market Estimation, 2015 – 2021
8.2.2.5.5.2.
Market Forecast, 2022 – 2030
8.2.3.
Others
8.2.3.1.
Definition
8.2.3.2.
Market Estimation and Penetration,
2015 – 2021
8.2.3.3.
Market Forecast, 2022 – 2030
8.2.3.4.
Compound Annual Growth Rate (CAGR)
8.2.3.5.
Regional Bifurcation
8.2.3.5.1.
North America
8.2.3.5.1.1.
Market Estimation, 2015 – 2021
8.2.3.5.1.2.
Market Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1.
Market Estimation, 2015 – 2021
8.2.3.5.2.2.
Market Forecast, 2022 – 2030
8.2.3.5.3.
Asia Pacific
8.2.3.5.3.1.
Market Estimation, 2015 – 2021
8.2.3.5.3.2.
Market Forecast, 2022 – 2030
8.2.3.5.4.
Middle East and Africa
8.2.3.5.4.1.
Market Estimation, 2015 – 2021
8.2.3.5.4.2.
Market Forecast, 2022 – 2030
8.2.3.5.5.
Latin America
8.2.3.5.5.1.
Market Estimation, 2015 – 2021
8.2.3.5.5.2.
Market Forecast, 2022 – 2030
8.3. Key Segment
for Channeling Investments
8.3.1. By Product Type
9.
Global Estrogen Receptor Agonist Market Analysis and Forecasts, 2022 – 2030
9.1.
Overview
9.2. Global
Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
9.2.1. Cancer
9.2.1.1.
Definition
9.2.1.2.
Market Estimation and Penetration,
2015 – 2021
9.2.1.3.
Market Forecast, 2022 – 2030
9.2.1.4.
Compound Annual Growth Rate (CAGR)
9.2.1.5.
Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1.
Market Estimation, 2015 – 2021
9.2.1.5.1.2.
Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1.
Market Estimation, 2015 – 2021
9.2.1.5.2.2.
Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia Pacific
9.2.1.5.3.1.
Market Estimation, 2015 – 2021
9.2.1.5.3.2.
Market Forecast, 2022 – 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1.
Market Estimation, 2015 – 2021
9.2.1.5.4.2.
Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin America
9.2.1.5.5.1.
Market Estimation, 2015 – 2021
9.2.1.5.5.2.
Market Forecast, 2022 – 2030
9.2.2. Fertility
9.2.2.1.
Definition
9.2.2.2.
Market Estimation and Penetration,
2015 – 2021
9.2.2.3.
Market Forecast, 2022 – 2030
9.2.2.4.
Compound Annual Growth
Rate (CAGR)
9.2.2.5.
Regional Bifurcation
|
9.2.2.5.1. |
North
America |
|
9.2.2.5.1.1. Market Estimation, 2015 – 2021 |
|
|
9.2.2.5.1.2. Market Forecast, 2022 – 2030 |
|
9.2.2.5.2. |
Europe |
|
|
9.2.2.5.2.1. Market Estimation, 2015 – 2021 |
|
|
9.2.2.5.2.2. Market Forecast, 2022 – 2030 |
|
9.2.2.5.3. |
Asia Pacific |
|
|
9.2.2.5.3.1. Market Estimation, 2015 – 2021 |
|
|
9.2.2.5.3.2. Market Forecast, 2022 – 2030 |
|
9.2.2.5.4. |
Middle East and
Africa |
|
|
9.2.2.5.4.1. Market Estimation, 2015 – 2021 |
|
|
9.2.2.5.4.2. Market Forecast, 2022 – 2030 |
|
9.2.2.5.5. |
Latin America |
|
|
|
9.2.2.5.5.1. Market Estimation, 2015 – 2021 |
|
|
9.2.2.5.5.2. Market Forecast, 2022 – 2030 |
9.2.3. PCOS |
|
|
9.2.3.1.
Definition
9.2.3.2.
Market Estimation and Penetration,
2015 – 2021
9.2.3.3.
Market Forecast, 2022 – 2030
9.2.3.4.
Compound Annual Growth Rate (CAGR)
9.2.3.5.
Regional Bifurcation
9.2.3.5.1.
North America
9.2.3.5.1.1.
Market Estimation, 2015 – 2021
9.2.3.5.1.2.
Market Forecast, 2022 – 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1.
Market Estimation, 2015 – 2021
9.2.3.5.2.2.
Market Forecast, 2022 – 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1.
Market Estimation, 2015 – 2021
9.2.3.5.3.2.
Market Forecast, 2022 – 2030
9.2.3.5.4.
Middle East and Africa
9.2.3.5.4.1.
Market Estimation, 2015 – 2021
9.2.3.5.4.2.
Market Forecast, 2022 – 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1.
Market Estimation, 2015 – 2021
9.2.3.5.5.2.
Market Forecast, 2022 – 2030
9.2.4.
Osteoporosis
9.2.4.1.
Definition
9.2.4.2.
Market Estimation and Penetration,
2015 – 2021
9.2.4.3.
Market Forecast, 2022 – 2030
9.2.4.4.
Compound Annual Growth Rate (CAGR)
9.2.4.5.
Regional Bifurcation
9.2.4.5.1.
North America
9.2.4.5.1.1.
Market Estimation, 2015 – 2021
9.2.4.5.1.2.
Market Forecast, 2022 – 2030
9.2.4.5.2. Europe
9.2.4.5.2.1.
Market Estimation, 2015 – 2021
9.2.4.5.2.2.
Market Forecast, 2022 – 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1.
Market Estimation, 2015 – 2021
9.2.4.5.3.2.
Market Forecast, 2022 – 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1.
Market Estimation, 2015 – 2021
9.2.4.5.4.2.
Market Forecast, 2022 – 2030
9.2.4.5.5.
Latin America
9.2.4.5.5.1.
Market Estimation, 2015 – 2021
9.2.4.5.5.2.
Market Forecast, 2022 – 2030
9.2.5. Neurodegenerative Disorders
(Including Multiple sclerosis
(MS))
9.2.5.1.
Definition
9.2.5.2.
Market Estimation and Penetration,
2015 – 2021
9.2.5.3.
Market Forecast, 2022 – 2030
9.2.5.4.
Compound Annual Growth Rate (CAGR)
9.2.5.5.
Regional Bifurcation
9.2.5.5.1.
North America
9.2.5.5.1.1.
Market Estimation, 2015 – 2021
9.2.5.5.1.2.
Market Forecast, 2022 – 2030
9.2.5.5.2. Europe
9.2.5.5.2.1.
Market Estimation, 2015 – 2021
9.2.5.5.2.2.
Market Forecast, 2022 – 2030
9.2.5.5.3.
Asia Pacific
9.2.5.5.3.1.
Market Estimation, 2015 – 2021
9.2.5.5.3.2.
Market Forecast, 2022 – 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1.
Market Estimation, 2015 – 2021
9.2.5.5.4.2.
Market Forecast, 2022 – 2030
9.2.5.5.5.
Latin America
9.2.5.5.5.1.
Market Estimation, 2015 – 2021
9.2.5.5.5.2.
Market Forecast, 2022 – 2030
9.2.6.
Inflammatory Diseases
9.2.6.1.
Definition
9.2.6.2.
Market Estimation and Penetration,
2015 – 2021
9.2.6.3.
Market Forecast, 2022 – 2030
9.2.6.4.
Compound Annual Growth Rate (CAGR)
9.2.6.5.
Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1.
Market Estimation, 2015 – 2021
9.2.6.5.1.2.
Market Forecast, 2022 – 2030
9.2.6.5.2. Europe
9.2.6.5.2.1.
Market Estimation, 2015 – 2021
9.2.6.5.2.2.
Market Forecast, 2022 – 2030
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1.
Market Estimation, 2015 – 2021
9.2.6.5.3.2.
Market Forecast, 2022 – 2030
9.2.6.5.4.
Middle East and Africa
9.2.6.5.4.1.
Market Estimation, 2015 – 2021
9.2.6.5.4.2.
Market Forecast, 2022 – 2030
9.2.6.5.5. Latin America
9.2.6.5.5.1.
Market Estimation, 2015 – 2021
9.2.6.5.5.2.
Market Forecast, 2022 – 2030
9.2.7.
Cardiovascular Health
9.2.7.1.
Definition
9.2.7.2.
Market Estimation and Penetration,
2015 – 2021
9.2.7.3.
Market Forecast, 2022 – 2030
9.2.7.4.
Compound Annual Growth Rate (CAGR)
9.2.7.5.
Regional Bifurcation
|
9.2.7.5.1. |
North
America |
|
9.2.7.5.1.1. Market Estimation, 2015 – 2021 |
|
|
9.2.7.5.1.2. Market Forecast, 2022 – 2030 |
|
9.2.7.5.2. |
Europe |
|
|
9.2.7.5.2.1. Market Estimation, 2015 – 2021 |
|
|
9.2.7.5.2.2. Market Forecast, 2022 – 2030 |
|
9.2.7.5.3. |
Asia Pacific |
|
|
9.2.7.5.3.1. Market Estimation, 2015 – 2021 |
|
|
9.2.7.5.3.2. Market Forecast, 2022 – 2030 |
|
9.2.7.5.4. |
Middle East and Africa |
|
|
9.2.7.5.4.1. Market Estimation, 2015 – 2021 |
|
|
9.2.7.5.4.2. Market Forecast, 2022 – 2030 |
|
9.2.7.5.5. |
Latin America |
|
|
|
9.2.7.5.5.1. Market Estimation, 2015 – 2021 |
|
|
9.2.7.5.5.2. Market Forecast, 2022 – 2030 |
9.2.8. Other |
|
|
9.2.8.1.
Definition
9.2.8.2.
Market Estimation and Penetration,
2015 – 2021
9.2.8.3.
Market Forecast, 2022 – 2030
9.2.8.4.
Compound Annual Growth Rate (CAGR)
9.2.8.5.
Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1.
Market Estimation, 2015 – 2021
9.2.8.5.1.2.
Market Forecast, 2022 – 2030
9.2.8.5.2.
Europe
9.2.8.5.2.1.
Market Estimation, 2015 – 2021
9.2.8.5.2.2.
Market Forecast, 2022 – 2030
9.2.8.5.3.
Asia Pacific
9.2.8.5.3.1.
Market Estimation, 2015 – 2021
9.2.8.5.3.2.
Market Forecast, 2022 – 2030
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1.
Market Estimation, 2015 – 2021
9.2.8.5.4.2.
Market Forecast, 2022 – 2030
9.2.8.5.5.
Latin America
9.2.8.5.5.1.
Market Estimation, 2015 – 2021
9.2.8.5.5.2.
Market Forecast, 2022 – 2030
9.3. Key Segment
for Channeling Investments
9.3.1. By Clinical Indication
10. Global Estrogen
Receptor Agonist Market Analysis and Forecasts, 2022 – 2030
10.1.
Overview
10.2. Global
Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Route of Administration
10.2.1. Oral
10.2.1.1.
Definition
10.2.1.2.
Market Estimation and Penetration,
2015 – 2021
10.2.1.3.
Market Forecast, 2022 – 2030
10.2.1.4.
Compound Annual Growth
Rate (CAGR)
10.2.1.5.
Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1.
Market Estimation, 2015 – 2021
10.2.1.5.1.2.
Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1.
Market Estimation, 2015 – 2021
10.2.1.5.2.2.
Market Forecast, 2022 – 2030
10.2.1.5.3.
Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 – 2021
10.2.1.5.3.2.
Market Forecast, 2022 – 2030 10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1.
Market Estimation, 2015 – 2021
10.2.1.5.4.2.
Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1.
Market Estimation, 2015 – 2021
10.2.1.5.5.2.
Market Forecast, 2022 – 2030
10.2.2. Parenteral
10.2.2.1.
Definition
10.2.2.2.
Market Estimation and Penetration,
2015 – 2021
10.2.2.3.
Market Forecast, 2022 – 2030
10.2.2.4.
Compound Annual Growth Rate (CAGR)
10.2.2.5.
Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1.
Market Estimation, 2015 – 2021
10.2.2.5.1.2.
Market Forecast, 2022 – 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 – 2021
10.2.2.5.2.2.
Market Forecast, 2022 – 2030
10.2.2.5.3.
Asia Pacific
10.2.2.5.3.1.
Market Estimation, 2015 –
2021
10.2.2.5.3.2.
Market Forecast, 2022 – 2030 10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 – 2021
10.2.2.5.4.2.
Market Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1.
Market Estimation, 2015 – 2021
10.2.2.5.5.2.
Market Forecast, 2022 – 2030
10.3. Key Segment
for Channeling Investments
10.3.1. By Route of Administration
11. Global Estrogen
Receptor Agonist Market Analysis
and Forecasts, 2022 – 2030
11.1.
Overview
11.2. Global
Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.2.1. Online
11.2.1.1.
Definition
11.2.1.2.
Market Estimation and Penetration,
2015 – 2021
11.2.1.3.
Market Forecast, 2022 – 2030
11.2.1.4.
Compound Annual Growth Rate (CAGR)
11.2.1.5.
Regional Bifurcation
11.2.1.5.1.
North America
11.2.1.5.1.1.
Market Estimation, 2015 – 2021
11.2.1.5.1.2.
Market Forecast, 2022 – 2030
11.2.1.5.2. Europe
11.2.1.5.2.1.
Market Estimation, 2015 – 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3.
Asia Pacific
11.2.1.5.3.1.
Market Estimation, 2015 – 2021
11.2.1.5.3.2.
Market Forecast, 2022 – 2030 11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1.
Market Estimation, 2015 – 2021
11.2.1.5.4.2.
Market Forecast, 2022 – 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1.
Market Estimation, 2015 – 2021
11.2.1.5.5.2.
Market Forecast, 2022 – 2030
11.2.2.
Offline
11.2.2.1.
Definition
11.2.2.2.
Market Estimation and Penetration, 2015 – 2021
11.2.2.3.
Market Forecast, 2022 – 2030
11.2.2.4.
Compound Annual Growth Rate (CAGR)
11.2.2.5.
Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1.
Market Estimation, 2015 – 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1.
Market Estimation, 2015 – 2021
11.2.2.5.2.2.
Market Forecast, 2022 – 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1.
Market Estimation, 2015 – 2021
11.2.2.5.3.2.
Market Forecast, 2022 – 2030 11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 – 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5.
Latin America
11.2.2.5.5.1.
Market Estimation, 2015 – 2021
11.2.2.5.5.2.
Market Forecast, 2022 – 2030
11.3. Key Segment
for Channeling Investments
11.3.1. By Distribution Channel
12. North
America Estrogen Receptor Agonist Market Analysis and Forecasts, 2022 – 2030
12.1.
Overview
12.1.1.
North America Estrogen
Receptor Agonist Market
Revenue (US$ Mn)
12.2. North
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Product
Type
12.2.1. Endogenous Estrogen
Receptor Agonist
12.2.2. Selective Estrogen
Receptor Agonist
12.2.3.
Others
12.3. North
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
12.3.1. Cancer
12.3.2. Fertility
12.3.3.
PCOS
12.3.4. Osteoporosis
12.3.5.
Neurodegenerative Disorders (Including Multiple sclerosis (MS))
12.3.6.
Inflammatory Diseases
12.3.7.
Cardiovascular Health
12.3.8. Other
12.4. North
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.4.1. Oral
12.4.2.
Parenteral
12.5. North
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.1. Online
12.5.2. Offline
12.6. North
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S Estrogen Receptor Agonist Market Revenue (US$ Mn)
and Forecasts, By Product
Type
12.6.1.1.1.
Endogenous Estrogen Receptor Agonist 12.6.1.1.2. Selective Estrogen Receptor
Agonist 12.6.1.1.3. Others
12.6.1.2.
U.S Estrogen Receptor Agonist Market Revenue (US$ Mn)
and Forecasts, By Clinical
Indication
12.6.1.2.1. Cancer
12.6.1.2.2.
Fertility
12.6.1.2.3. PCOS
12.6.1.2.4.
Osteoporosis
12.6.1.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 12.6.1.2.6. Inflammatory Diseases
12.6.1.2.7. Cardiovascular Health
12.6.1.2.8.
Other
12.6.1.3.
U.S Estrogen Receptor Agonist Market Revenue (US$ Mn)
and Forecasts, By Route
of Administration
12.6.1.3.1. Oral
12.6.1.3.2.
Parenteral
12.6.1.4.
U.S Estrogen Receptor Agonist Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
12.6.1.4.1. Online
12.6.1.4.2. Offline
12.6.2.
Canada
12.6.2.1.
Canada Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
12.6.2.1.1.
Endogenous Estrogen Receptor Agonist 12.6.2.1.2. Selective Estrogen Receptor
Agonist 12.6.2.1.3. Others
12.6.2.2.
Canada Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
12.6.2.2.1. Cancer
12.6.2.2.2.
Fertility
12.6.2.2.3.
PCOS
12.6.2.2.4. Osteoporosis
12.6.2.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 12.6.2.2.6. Inflammatory Diseases
12.6.2.2.7. Cardiovascular Health
12.6.2.2.8.
Other
12.6.2.3.
Canada Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
12.6.2.3.1. Oral
12.6.2.3.2.
Parenteral
12.6.2.4.
Canada Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
12.6.2.4.1. Online
12.6.2.4.2.
Offline
12.6.3.
Mexico
12.6.3.1.
Mexico Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
12.6.3.1.1.
Endogenous Estrogen Receptor Agonist 12.6.3.1.2. Selective Estrogen Receptor
Agonist 12.6.3.1.3. Others
12.6.3.2.
Mexico Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
12.6.3.2.1. Cancer
12.6.3.2.2.
Fertility
12.6.3.2.3.
PCOS
12.6.3.2.4.
Osteoporosis
12.6.3.2.5.
Neurodegenerative Disorders (Including Multiple sclerosis
(MS)) 12.6.3.2.6. Inflammatory Diseases
12.6.3.2.7. Cardiovascular Health
12.6.3.2.8. Other
12.6.3.3.
Mexico Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
12.6.3.3.1. Oral
12.6.3.3.2. Parenteral
12.6.3.4.
Mexico Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
12.6.3.4.1. Online
12.6.3.4.2. Offline
12.6.4.
Rest of North America
12.6.4.1.
Rest of North America Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Product Type
12.6.4.1.1.
Endogenous Estrogen Receptor Agonist 12.6.4.1.2. Selective Estrogen Receptor
Agonist 12.6.4.1.3. Others
12.6.4.2.
Rest of North America Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Clinical Indication
12.6.4.2.1. Cancer
12.6.4.2.2.
Fertility
12.6.4.2.3.
PCOS
12.6.4.2.4.
Osteoporosis
12.6.4.2.5.
Neurodegenerative Disorders (Including Multiple sclerosis
(MS)) 12.6.4.2.6. Inflammatory Diseases
12.6.4.2.7. Cardiovascular Health
12.6.4.2.8.
Other
12.6.4.3.
Rest of North America Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.4.3.1. Oral
12.6.4.3.2. Parenteral
12.6.4.4.
Rest of North America Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.4.4.1. Online
12.6.4.4.2.
Offline
12.7.
Key Segment
for Channeling Investments
12.7.1.
By Country
12.7.2.
By Product Type
12.7.3.
By Clinical Indication
12.7.4. By Route of Administration
12.7.5.
By Distribution Channel
13. Europe Estrogen
Receptor Agonist Market Analysis
and Forecasts, 2022 – 2030
13.1.
Overview
13.1.1.
Europe Estrogen Receptor Agonist Market Revenue (US$ Mn)
13.2. Europe
Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Product Type
13.2.1. Endogenous Estrogen
Receptor Agonist
13.2.2.
Selective Estrogen Receptor
Agonist
13.2.3.
Others
13.3. Europe
Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
13.3.1. Cancer
13.3.2.
Fertility
13.3.3.
PCOS
13.3.4. Osteoporosis
13.3.5.
Neurodegenerative Disorders (Including Multiple sclerosis (MS))
13.3.6. Inflammatory Diseases
13.3.7.
Cardiovascular Health
13.3.8.
Other
13.4. Europe
Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.4.1. Oral
13.4.2.
Parenteral
13.5. Europe
Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.1. Online
13.5.2. Offline
13.6. Europe Estrogen Receptor
Agonist Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.1.
France
13.6.1.1.
France Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
13.6.1.1.1.
Endogenous Estrogen Receptor Agonist 13.6.1.1.2. Selective Estrogen Receptor
Agonist 13.6.1.1.3. Others
13.6.1.2.
France Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
13.6.1.2.1. Cancer
13.6.1.2.2.
Fertility
13.6.1.2.3.
PCOS
13.6.1.2.4.
Osteoporosis
13.6.1.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 13.6.1.2.6. Inflammatory Diseases
13.6.1.2.7. Cardiovascular Health
13.6.1.2.8.
Other
13.6.1.3.
France Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.6.1.3.1. Oral
13.6.1.3.2.
Parenteral
13.6.1.4.
France Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.1.4.1. Online
13.6.1.4.2.
Offline
13.6.2.
The UK
13.6.2.1.
The UK Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
13.6.2.1.1.
Endogenous Estrogen Receptor Agonist 13.6.2.1.2. Selective Estrogen Receptor
Agonist 13.6.2.1.3. Others
13.6.2.2.
The UK Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
13.6.2.2.1. Cancer
13.6.2.2.2. Fertility
13.6.2.2.3.
PCOS
13.6.2.2.4.
Osteoporosis
13.6.2.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 13.6.2.2.6. Inflammatory Diseases
13.6.2.2.7. Cardiovascular Health
13.6.2.2.8.
Other
13.6.2.3.
The UK Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.6.2.3.1. Oral
13.6.2.3.2.
Parenteral
13.6.2.4.
The UK Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.2.4.1. Online
13.6.2.4.2. Offline
13.6.3.
Spain
13.6.3.1.
Spain Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
13.6.3.1.1.
Endogenous Estrogen Receptor Agonist 13.6.3.1.2. Selective Estrogen Receptor
Agonist 13.6.3.1.3. Others
13.6.3.2.
Spain Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
13.6.3.2.1. Cancer
13.6.3.2.2. Fertility
13.6.3.2.3.
PCOS
13.6.3.2.4.
Osteoporosis
13.6.3.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 13.6.3.2.6. Inflammatory Diseases
13.6.3.2.7. Cardiovascular Health
13.6.3.2.8. Other
13.6.3.3.
Spain Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.6.3.3.1. Oral
13.6.3.3.2.
Parenteral
13.6.3.4.
Spain Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.3.4.1. Online
13.6.3.4.2. Offline
13.6.4.
Germany
13.6.4.1.
Germany Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
13.6.4.1.1.
Endogenous Estrogen Receptor Agonist 13.6.4.1.2. Selective Estrogen Receptor
Agonist 13.6.4.1.3. Others
13.6.4.2.
Germany Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
13.6.4.2.1. Cancer
13.6.4.2.2.
Fertility
13.6.4.2.3.
PCOS
13.6.4.2.4.
Osteoporosis
13.6.4.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 13.6.4.2.6. Inflammatory Diseases
13.6.4.2.7. Cardiovascular Health
13.6.4.2.8. Other
13.6.4.3.
Germany Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.6.4.3.1. Oral
13.6.4.3.2. Parenteral
13.6.4.4.
Germany Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.5. Italy
13.6.4.4.1. Online
13.6.4.4.2. Offline
13.6.5.1.
Italy Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product
Type
13.6.5.1.1.
Endogenous Estrogen Receptor Agonist 13.6.5.1.2. Selective Estrogen Receptor
Agonist 13.6.5.1.3. Others
13.6.5.2.
Italy Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
13.6.5.2.1. Cancer
13.6.5.2.2. Fertility
13.6.5.2.3. PCOS
13.6.5.2.4.
Osteoporosis
13.6.5.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 13.6.5.2.6. Inflammatory Diseases
13.6.5.2.7. Cardiovascular Health
13.6.5.2.8.
Other
13.6.5.3.
Italy Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route
of Administration
13.6.5.3.1. Oral
13.6.5.3.2. Parenteral
13.6.5.4.
Italy Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.5.4.1. Online
13.6.5.4.2.
Offline
13.6.6.
Nordic Countries
13.6.6.1.
Nordic Countries Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Product Type
13.6.6.1.1.
Endogenous Estrogen Receptor Agonist 13.6.6.1.2. Selective Estrogen Receptor
Agonist 13.6.6.1.3. Others
13.6.6.2.
Nordic Countries Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Clinical
Indication
13.6.6.2.1. Cancer
13.6.6.2.2.
Fertility
13.6.6.2.3.
PCOS
13.6.6.2.4.
Osteoporosis
13.6.6.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 13.6.6.2.6. Inflammatory Diseases
13.6.6.2.7. Cardiovascular Health
13.6.6.2.8.
Other
13.6.6.3.
Nordic Countries Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.6.3.1. Oral
13.6.6.3.2.
Parenteral
13.6.6.4.
Nordic Countries Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.6.4.1. Online
13.6.6.4.2.
Offline
13.6.6.5.
Nordic Countries Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux Union Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Product Type
13.6.7.1.1.
Endogenous Estrogen Receptor Agonist 13.6.7.1.2. Selective Estrogen Receptor
Agonist 13.6.7.1.3. Others
13.6.7.2.
Benelux Union Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Clinical
Indication
13.6.7.2.1. Cancer
13.6.7.2.2.
Fertility
13.6.7.2.3. PCOS
13.6.7.2.4.
Osteoporosis
13.6.7.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 13.6.7.2.6. Inflammatory Diseases
13.6.7.2.7. Cardiovascular Health
13.6.7.2.8.
Other
13.6.7.3.
Benelux Union Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.7.3.1. Oral
13.6.7.3.2.
Parenteral
13.6.7.4.
Benelux Union Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
13.6.7.4.1. Online
13.6.7.4.2. Offline
13.6.7.5.
Benelux Union Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3.
Luxembourg
13.6.8.
Rest of Europe
13.6.8.1.
Rest of Europe Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Product Type
13.6.8.1.1.
Endogenous Estrogen Receptor Agonist 13.6.8.1.2. Selective Estrogen Receptor
Agonist 13.6.8.1.3. Others
13.6.8.2.
Rest of Europe Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Clinical
Indication
13.6.8.2.1. Cancer
13.6.8.2.2.
Fertility
13.6.8.2.3.
PCOS
13.6.8.2.4. Osteoporosis
13.6.8.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 13.6.8.2.6. Inflammatory Diseases
13.6.8.2.7. Cardiovascular Health
13.6.8.2.8.
Other
13.6.8.3.
Rest of Europe Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.8.3.1. Oral
13.6.8.3.2.
Parenteral
13.6.8.4.
Rest of Europe Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.8.4.1. Online
13.6.8.4.2.
Offline
13.7. Key Segment for Channeling Investments
13.7.1.
By Country
13.7.2.
By Product Type
13.7.3. By Clinical Indication
13.7.4.
By Route of Administration
13.7.5. By Distribution Channel
14. Asia Pacific
Estrogen Receptor Agonist
Market Analysis and Forecasts, 2022 – 2030
14.1.
Overview
14.1.1.
Asia Pacific Estrogen
Receptor Agonist Market
Revenue (US$ Mn)
14.2. Asia
Pacific Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Product
Type
14.2.1. Endogenous Estrogen
Receptor Agonist
14.2.2. Selective Estrogen
Receptor Agonist
14.2.3.
Others
14.3. Asia
Pacific Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.3.1. Cancer
14.3.2.
Fertility
14.3.3.
PCOS
14.3.4.
Osteoporosis
14.3.5. Neurodegenerative Disorders (Including Multiple sclerosis (MS))
14.3.6.
Inflammatory Diseases
14.3.7. Cardiovascular Health
14.3.8.
Other
14.4. Asia
Pacific Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.4.1. Oral
14.4.2.
Parenteral
14.5. Asia
Pacific Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.1. Online
14.5.2.
Offline
14.6. Asia
Pacific Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
14.6.1.1.1.
Endogenous Estrogen Receptor Agonist 14.6.1.1.2. Selective Estrogen Receptor
Agonist 14.6.1.1.3. Others
14.6.1.2.
China Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
14.6.1.2.1. Cancer
14.6.1.2.2. Fertility
14.6.1.2.3.
PCOS
14.6.1.2.4.
Osteoporosis
14.6.1.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 14.6.1.2.6. Inflammatory Diseases
14.6.1.2.7. Cardiovascular Health
14.6.1.2.8. Other
14.6.1.3.
China Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.6.1.3.1. Oral
14.6.1.3.2. Parenteral
14.6.1.4.
China Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.1.4.1. Online
14.6.1.4.2. Offline
14.6.2.
Japan
14.6.2.1.
Japan Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
14.6.2.1.1.
Endogenous Estrogen Receptor Agonist 14.6.2.1.2. Selective Estrogen Receptor
Agonist 14.6.2.1.3. Others
14.6.2.2.
Japan Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
14.6.2.2.1. Cancer
14.6.2.2.2.
Fertility
14.6.2.2.3.
PCOS
14.6.2.2.4.
Osteoporosis
14.6.2.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 14.6.2.2.6. Inflammatory Diseases
14.6.2.2.7. Cardiovascular Health
14.6.2.2.8.
Other
14.6.2.3.
Japan Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.6.2.3.1. Oral
14.6.2.3.2. Parenteral
14.6.2.4.
Japan Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.2.4.1. Online
14.6.2.4.2.
Offline
14.6.3. India
14.6.3.1.
India Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product
Type
14.6.3.1.1.
Endogenous Estrogen Receptor Agonist 14.6.3.1.2. Selective Estrogen Receptor
Agonist 14.6.3.1.3. Others
14.6.3.2.
India Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
14.6.3.2.1. Cancer
14.6.3.2.2.
Fertility
14.6.3.2.3. PCOS
14.6.3.2.4.
Osteoporosis
14.6.3.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 14.6.3.2.6. Inflammatory Diseases
14.6.3.2.7. Cardiovascular Health
14.6.3.2.8.
Other
14.6.3.3.
India Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route
of Administration
14.6.3.3.1. Oral
14.6.3.3.2. Parenteral
14.6.3.4.
India Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.3.4.1. Online
14.6.3.4.2.
Offline
14.6.4. New Zealand
14.6.4.1.
New Zealand Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Product Type
14.6.4.1.1.
Endogenous Estrogen Receptor Agonist 14.6.4.1.2. Selective Estrogen Receptor
Agonist 14.6.4.1.3. Others
14.6.4.2.
New Zealand Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Clinical
Indication
14.6.4.2.1. Cancer
14.6.4.2.2.
Fertility
14.6.4.2.3. PCOS
14.6.4.2.4.
Osteoporosis
14.6.4.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 14.6.4.2.6. Inflammatory Diseases
14.6.4.2.7. Cardiovascular Health
14.6.4.2.8.
Other
14.6.4.3.
New Zealand Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.4.3.1. Oral
14.6.4.3.2. Parenteral
14.6.4.4.
New Zealand Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
14.6.4.4.1. Online
14.6.4.4.2.
Offline
14.6.5. Australia
14.6.5.1.
Australia Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Product Type
14.6.5.1.1.
Endogenous Estrogen Receptor Agonist 14.6.5.1.2. Selective Estrogen Receptor
Agonist 14.6.5.1.3. Others
14.6.5.2.
Australia Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
14.6.5.2.1. Cancer
14.6.5.2.2.
Fertility
14.6.5.2.3.
PCOS
14.6.5.2.4.
Osteoporosis
14.6.5.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 14.6.5.2.6. Inflammatory Diseases
14.6.5.2.7. Cardiovascular Health
14.6.5.2.8.
Other
14.6.5.3.
Australia Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.5.3.1. Oral
14.6.5.3.2. Parenteral
14.6.5.4.
Australia Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
14.6.5.4.1. Online
14.6.5.4.2. Offline
14.6.6.
South Korea
14.6.6.1.
South Korea Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Product Type
14.6.6.1.1.
Endogenous Estrogen Receptor Agonist 14.6.6.1.2. Selective Estrogen Receptor
Agonist 14.6.6.1.3. Others
14.6.6.2.
South Korea Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Clinical
Indication
14.6.6.2.1. Cancer
14.6.6.2.2. Fertility
14.6.6.2.3.
PCOS
14.6.6.2.4.
Osteoporosis
14.6.6.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 14.6.6.2.6. Inflammatory Diseases
14.6.6.2.7. Cardiovascular Health
14.6.6.2.8. Other
14.6.6.3.
South Korea Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.6.3.1. Oral
14.6.6.3.2. Parenteral
14.6.6.4.
South Korea Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
14.6.6.4.1. Online
14.6.6.4.2.
Offline
14.6.7.
Southeast Asia
14.6.7.1.
Southeast Asia Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Product Type
14.6.7.1.1.
Endogenous Estrogen Receptor Agonist 14.6.7.1.2. Selective Estrogen Receptor
Agonist 14.6.7.1.3. Others
14.6.7.2.
Southeast Asia Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Clinical
Indication
14.6.7.2.1. Cancer
14.6.7.2.2.
Fertility
14.6.7.2.3.
PCOS
14.6.7.2.4. Osteoporosis
14.6.7.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 14.6.7.2.6. Inflammatory Diseases
14.6.7.2.7. Cardiovascular Health
14.6.7.2.8.
Other
14.6.7.3.
Southeast Asia Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.7.3.1. Oral
14.6.7.3.2.
Parenteral
14.6.7.4.
Southeast Asia Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.7.4.1. Online
14.6.7.4.2.
Offline
14.6.7.5.
Southeast Asia Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of Asia Pacific Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Product Type
14.6.8.1.1.
Endogenous Estrogen Receptor Agonist 14.6.8.1.2. Selective Estrogen Receptor
Agonist 14.6.8.1.3. Others
14.6.8.2.
Rest of Asia Pacific Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Clinical
Indication
14.6.8.2.1. Cancer
14.6.8.2.2.
Fertility
14.6.8.2.3.
PCOS
14.6.8.2.4.
Osteoporosis
14.6.8.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 14.6.8.2.6. Inflammatory Diseases
14.6.8.2.7. Cardiovascular Health
14.6.8.2.8.
Other
14.6.8.3.
Rest of Asia Pacific Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.8.3.1. Oral
14.6.8.3.2.
Parenteral
14.6.8.4.
Rest of Asia Pacific Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.8.4.1. Online
14.6.8.4.2.
Offline
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2.
By Product Type
14.7.3.
By Clinical Indication
14.7.4.
By Route of Administration
14.7.5. By Distribution Channel
15. Middle
East and Africa Estrogen Receptor Agonist Market Analysis and Forecasts, 2022 –
2030
15.1.
Overview
15.1.1.
Middle East and Africa Estrogen
Receptor Agonist Market
Revenue (US$ Mn)
15.2. Middle East
and Africa Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Product Type
15.2.1. Endogenous Estrogen
Receptor Agonist
15.2.2. Selective Estrogen
Receptor Agonist
15.2.3.
Others
15.3. Middle East
and Africa Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.3.1. Cancer
15.3.2.
Fertility
15.3.3. PCOS
15.3.4.
Osteoporosis
15.3.5.
Neurodegenerative Disorders (Including Multiple sclerosis (MS))
15.3.6.
Inflammatory Diseases
15.3.7. Cardiovascular Health
15.3.8.
Other
15.4. Middle East
and Africa Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.4.1. Oral
15.4.2. Parenteral
15.5. Middle East
and Africa Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.5.1. Online
15.5.2.
Offline
15.6. Middle East
and Africa Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi Arabia Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Product Type
15.6.1.1.1.
Endogenous Estrogen Receptor Agonist 15.6.1.1.2. Selective Estrogen Receptor
Agonist 15.6.1.1.3. Others
15.6.1.2.
Saudi Arabia Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Clinical
Indication
15.6.1.2.1. Cancer
15.6.1.2.2. Fertility
15.6.1.2.3.
PCOS
15.6.1.2.4.
Osteoporosis
15.6.1.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 15.6.1.2.6. Inflammatory Diseases
15.6.1.2.7. Cardiovascular Health
15.6.1.2.8. Other
15.6.1.3.
Saudi Arabia Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.6.1.3.1. Oral
15.6.1.3.2. Parenteral
15.6.1.4.
Saudi Arabia Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
15.6.2. UAE
15.6.1.4.1. Online
15.6.1.4.2.
Offline
15.6.2.1.
UAE Estrogen Receptor Agonist Market Revenue (US$ Mn)
and Forecasts, By Product
Type
15.6.2.1.1.
Endogenous Estrogen Receptor Agonist 15.6.2.1.2. Selective Estrogen Receptor
Agonist 15.6.2.1.3. Others
15.6.2.2.
UAE Estrogen Receptor Agonist Market Revenue (US$ Mn)
and Forecasts, By Clinical
Indication
15.6.2.2.1. Cancer
15.6.2.2.2. Fertility
15.6.2.2.3. PCOS
15.6.2.2.4.
Osteoporosis
15.6.2.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 15.6.2.2.6. Inflammatory Diseases
15.6.2.2.7. Cardiovascular Health
15.6.2.2.8.
Other
15.6.2.3.
UAE Estrogen Receptor Agonist Market Revenue (US$ Mn)
and Forecasts, By Route
of Administration
15.6.2.3.1. Oral
15.6.2.3.2. Parenteral
15.6.2.4.
UAE Estrogen Receptor Agonist Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
15.6.2.4.1. Online
15.6.2.4.2.
Offline
15.6.3.
Egypt
15.6.3.1.
Egypt Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
15.6.3.1.1.
Endogenous Estrogen Receptor Agonist 15.6.3.1.2. Selective Estrogen Receptor
Agonist 15.6.3.1.3. Others
15.6.3.2.
Egypt Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
15.6.3.2.1. Cancer
15.6.3.2.2.
Fertility
15.6.3.2.3.
PCOS
15.6.3.2.4.
Osteoporosis
15.6.3.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 15.6.3.2.6. Inflammatory Diseases
15.6.3.2.7. Cardiovascular Health
15.6.3.2.8.
Other
15.6.3.3.
Egypt Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.6.3.3.1. Oral
15.6.3.3.2.
Parenteral
15.6.3.4.
Egypt Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
15.6.3.4.1. Online
15.6.3.4.2.
Offline
15.6.4.
Kuwait
15.6.4.1.
Kuwait Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
15.6.4.1.1.
Endogenous Estrogen Receptor Agonist 15.6.4.1.2. Selective Estrogen Receptor
Agonist 15.6.4.1.3. Others
15.6.4.2.
Kuwait Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
15.6.4.2.1. Cancer
15.6.4.2.2. Fertility
15.6.4.2.3.
PCOS
15.6.4.2.4.
Osteoporosis
15.6.4.2.5.
Neurodegenerative Disorders (Including Multiple sclerosis
(MS)) 15.6.4.2.6. Inflammatory Diseases
15.6.4.2.7. Cardiovascular Health
15.6.4.2.8.
Other
15.6.4.3.
Kuwait Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.6.4.3.1. Oral
15.6.4.3.2.
Parenteral
15.6.4.4.
Kuwait Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
15.6.4.4.1. Online
15.6.4.4.2. Offline
15.6.5.
South Africa
15.6.5.1.
South Africa Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Product Type
15.6.5.1.1.
Endogenous Estrogen Receptor Agonist 15.6.5.1.2. Selective Estrogen Receptor
Agonist 15.6.5.1.3. Others
15.6.5.2.
South Africa Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Clinical
Indication
15.6.5.2.1. Cancer
15.6.5.2.2. Fertility
15.6.5.2.3.
PCOS
15.6.5.2.4.
Osteoporosis
15.6.5.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 15.6.5.2.6. Inflammatory Diseases
15.6.5.2.7. Cardiovascular Health
15.6.5.2.8. Other
15.6.5.3.
South Africa Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.6.5.3.1. Oral
15.6.5.3.2.
Parenteral
15.6.5.4.
South Africa Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
15.6.5.4.1. Online
15.6.5.4.2. Offline
15.6.6.
Rest of Middle
East & Africa
15.6.6.1.
Rest of Middle East & Africa Estrogen Receptor
Agonist Market Revenue (US$ Mn) and Forecasts, By Product Type
15.6.6.1.1.
Endogenous Estrogen Receptor Agonist 15.6.6.1.2. Selective Estrogen Receptor
Agonist 15.6.6.1.3. Others
15.6.6.2.
Rest of Middle East & Africa Estrogen Receptor
Agonist Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.6.6.2.1. Cancer
15.6.6.2.2.
Fertility
15.6.6.2.3.
PCOS
15.6.6.2.4.
Osteoporosis
15.6.6.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 15.6.6.2.6. Inflammatory Diseases
15.6.6.2.7. Cardiovascular Health
15.6.6.2.8. Other
15.6.6.3.
Rest of Middle East & Africa Estrogen Receptor
Agonist Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.6.3.1. Oral
15.6.6.3.2. Parenteral
15.6.6.4.
Rest of Middle East & Africa Estrogen Receptor
Agonist Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.6.4.1. Online
15.6.6.4.2.
Offline
15.7.
Key Segment
for Channeling Investments
15.7.1.
By Country
15.7.2.
By Product Type
15.7.3.
By Clinical Indication
15.7.4. By Route of Administration
15.7.5.
By Distribution Channel
16. Latin
America Estrogen Receptor
Agonist Market Analysis
and Forecasts, 2022 – 2030
16.1.
Overview
16.1.1.
Latin America Estrogen
Receptor Agonist Market
Revenue (US$ Mn)
16.2. Latin
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Product
Type
16.2.1. Endogenous Estrogen
Receptor Agonist
16.2.2.
Selective Estrogen Receptor Agonist
16.2.3. Others
16.3. Latin
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.3.1. Cancer
16.3.2. Fertility
16.3.3.
PCOS
16.3.4.
Osteoporosis
16.3.5. Neurodegenerative Disorders (Including Multiple sclerosis (MS))
16.3.6.
Inflammatory Diseases
16.3.7.
Cardiovascular Health
16.3.8.
Other
16.4. Latin
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.4.1. Oral
16.4.2. Parenteral
16.5. Latin
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.5.1. Online
16.5.2. Offline
16.6. Latin
America Estrogen Receptor Agonist Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Product Type
16.6.1.1.1. Endogenous Estrogen
Receptor Agonist
16.6.1.1.2.
Selective Estrogen Receptor Agonist 16.6.1.1.3. Others
16.6.1.2.
Brazil Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Clinical
Indication
16.6.1.2.1. Cancer
16.6.1.2.2.
Fertility
16.6.1.2.3. PCOS
16.6.1.2.4.
Osteoporosis
16.6.1.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 16.6.1.2.6. Inflammatory Diseases
16.6.1.2.7. Cardiovascular Health
16.6.1.2.8. Other
16.6.1.3.
Brazil Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.6.1.3.1. Oral
16.6.1.3.2.
Parenteral
16.6.1.4.
Brazil Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
16.6.1.4.1. Online
16.6.1.4.2.
Offline
16.6.2.
Argentina
16.6.2.1.
Argentina Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Product Type
16.6.2.1.1.
Endogenous Estrogen Receptor Agonist 16.6.2.1.2. Selective Estrogen Receptor
Agonist 16.6.2.1.3. Others
16.6.2.2.
Argentina Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Clinical
Indication
16.6.2.2.1. Cancer
16.6.2.2.2.
Fertility
16.6.2.2.3. PCOS
16.6.2.2.4.
Osteoporosis
16.6.2.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 16.6.2.2.6. Inflammatory Diseases
16.6.2.2.7. Cardiovascular Health
16.6.2.2.8.
Other
16.6.2.3.
Argentina Estrogen Receptor Agonist Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.6.2.3.1. Oral
16.6.2.3.2.
Parenteral
16.6.2.4.
Argentina Estrogen Receptor Agonist Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
16.6.2.4.1. Online
16.6.2.4.2. Offline
16.6.3.
Rest of Latin America
16.6.3.1.
Rest of Latin America Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Product Type
16.6.3.1.1.
Endogenous Estrogen Receptor Agonist 16.6.3.1.2. Selective Estrogen Receptor
Agonist 16.6.3.1.3. Others
16.6.3.2.
Rest of Latin America Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.6.3.2.1. Cancer
16.6.3.2.2.
Fertility
16.6.3.2.3.
PCOS
16.6.3.2.4.
Osteoporosis
16.6.3.2.5.
Neurodegenerative Disorders (Including Multiple
sclerosis (MS)) 16.6.3.2.6. Inflammatory Diseases
16.6.3.2.7. Cardiovascular Health
16.6.3.2.8.
Other
16.6.3.3.
Rest of Latin America Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.6.3.3.1. Oral
16.6.3.3.2.
Parenteral
16.6.3.4.
Rest of Latin America Estrogen Receptor Agonist Market
Revenue (US$ Mn) and Forecasts, By Distribution
Channel
16.6.3.4.1. Online
16.6.3.4.2.
Offline
16.7. Key Segment for Channeling Investments
16.7.1.
By Country
16.7.2.
By Product Type
16.7.3. By Clinical Indication
16.7.4.
By Route of Administration
16.7.5. By Distribution Channel
17. Competitive Benchmarking
17.1.
Market Share
Analysis, 2021
17.2. Global Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2.
Product Launches
17.2.3.
Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1.
AstraZeneca.
18.1.1.
Company Details
18.1.2.
Company Overview
18.1.3.
Product Offerings
18.1.4. Key Developments
18.1.5.
Financial Analysis
18.1.6.
SWOT Analysis
18.1.7.
Business Strategies
18.2. Eli Lilly and Company
18.2.1. Company Details
18.2.2.
Company Overview
18.2.3. Product Offerings
18.2.4.
Key Developments
18.2.5.
Financial Analysis
18.2.6.
SWOT Analysis
18.2.7. Business Strategies
18.3. ESTRIGENIX
18.3.1.
Company Details
18.3.2.
Company Overview
18.3.3.
Product Offerings
18.3.4. Key Developments
18.3.5.
Financial Analysis
18.3.6. SWOT Analysis
18.3.7.
Business Strategies
18.4. Karo Pharma AB
18.4.1.
Company Details
18.4.2.
Company Overview
18.4.3. Product Offerings
18.4.4.
Key Developments
18.4.5.
Financial Analysis
18.4.6. SWOT Analysis
18.4.7.
Business Strategies
18.5. Merck KGaA
18.5.1. Company Details
18.5.2.
Company Overview
18.5.3.
Product Offerings
18.5.4.
Key Developments
18.5.5. Financial Analysis
18.5.6.
SWOT Analysis
18.5.7. Business Strategies
18.6. Oasmia Pharmaceutical AB
18.6.1.
Company Details
18.6.2.
Company Overview
18.6.3. Product Offerings
18.6.4.
Key Developments
18.6.5.
Financial Analysis
18.6.6.
SWOT Analysis
18.6.7.
Business Strategies
18.7. Oncternal
Therapeutics.
18.7.1.
Company Details
18.7.2. Company Overview
18.7.3.
Product Offerings
18.7.4.
Key Developments
18.7.5.
Financial Analysis
18.7.6. SWOT Analysis
18.7.7.
Business Strategies
18.8. Pfizer Inc.
18.8.1.
Company Details
18.8.2.
Company Overview
18.8.3. Product Offerings
18.8.4.
Key Developments
18.8.5. Financial Analysis
18.8.6.
SWOT Analysis
18.8.7.
Business Strategies
18.9. Tocris Bioscience
18.9.1.
Company Details
18.9.2. Company Overview
18.9.3.
Product Offerings
18.9.4.
Key Developments
18.9.5. Financial Analysis
18.9.6.
SWOT Analysis
18.9.7.
Business Strategies
18.10.
Tokyo Chemical
Industry Co., Ltd.
18.10.1.
Company Details
18.10.2.
Company Overview
18.10.3.
Product Offerings
18.10.4. Key Developments
18.10.5.
Financial Analysis
18.10.6. SWOT Analysis
18.10.7.
Business Strategies
18.11. Other Market Participants
19. Key Findings
Note:
This ToC is tentative and can be changed according to the research study
conducted during the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.